Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $65.20 USD
Change Today -0.05 / -0.08%
Volume 1.5M
XON On Other Exchanges
New York
As of 8:04 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/15 - $67.91
52 Week Low
10/9/14 - $15.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

480 Employees
Last Reported Date: 03/2/15
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: $382.2K
Chief Operating Officer
Total Annual Compensation: $2.3M
Head of Health Sector and Senior Vice Preside...
Total Annual Compensation: $485.3K
Senior Vice President of Energy Sector
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2014.

intrexon corp (XON) Key Developments

Intrexon Corporation Announces Executive Appointments

Intrexon Corporation announced three additions to the executive team -- Jack A. Bobo, as Senior Vice President, Chief Communications Officer, Samuel Broder, M.D., as Senior Vice President, Head of Health Sector, and Joel Liffmann as Senior Vice President, Finance. Mr. Bobo joins Intrexon from the U.S. Department of State where he has worked for the past thirteen years, most recently as Senior Advisor for Food Policy following his positions as Senior Advisor for Biotechnology as well as Chief, Biotechnology and Textile Trade Division. Through these key roles Mr. Bobo was responsible for global outreach to foreign audiences and senior foreign officials across a variety of issues and led or participated in bilateral trade discussions and negotiations. Dr. Broder has an extensive career in health and is welcomed back to Intrexon in the role as Head of the Health Sector, succeeding Dr. Gregory Frost. Previously he served as Chairman of the Health Sector and Executive Vice President of Scientific and Public Affairs. Prior to Intrexon, Dr. Broder was Executive Vice President and Chief Medical Officer at Celera and Senior Vice President of Research and Development at IVAX Corporation. He also served as Director of the National Cancer Institute (NCI) for six years. Most recently Mr. Liffmann served as Executive Vice President of Corporate Development at Health Grades Inc., where he was responsible for researching and managing growth initiatives, evaluating and negotiating business opportunities, managing specific legal activities and partnering with other corporate leaders. Prior to Health Grades, Joel was a Senior Advisor to Vestar Capital Partners and was previously a Partner at Oracle Investment Management Inc., where he specialized in private company investing and merchant banking in health care, bioscience, and related industries.

Intrexon Corporation Presents at Third Annual GTL Technology Forum, Jul-29-2015 11:20 AM

Intrexon Corporation Presents at Third Annual GTL Technology Forum, Jul-29-2015 11:20 AM. Venue: Norris Conference Centers, City Centre, 816 Town and Country Blvd, Ste 210, Houston, TX 77024, United States. Speakers: Robert F. Walsh, Senior Vice President of Energy Sector.

Intrexon Corporation(NYSE:XON) added to Russell 1000 Index

Intrexon Corporation has been added to Russell 1000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $65.20 USD -0.05

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $195.73 USD -1.71
Photon Technology International Inc $0.0003 USD 0.00
MorphoSys AG €74.86 EUR +1.31
XOMA Corp $0.77 USD +0.043
View Industry Companies

Industry Analysis


Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 70.7x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 70.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at